Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | SMO W281C |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
SMO W281C | Advanced Solid Tumor | decreased response | Taladegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). | 25759019 | |
SMO W281C | Advanced Solid Tumor | sensitive | JQ1 | Preclinical | Actionable | In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). | 25759019 | |
SMO W281C | basal cell carcinoma | resistant | Vismodegib | Preclinical | Actionable | In a preclinical study, a transformed cell line expressing SMO W281C was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). | 25759020 | |
SMO W281C | Advanced Solid Tumor | decreased response | Sonidegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019). | 25759019 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|